New research could lead to pharmacological treatments for chronic pancreatitis

June 12, 2015 by Tracie White, Stanford University Medical Center

The pancreas is a tricky organ for researchers and surgeons alike because of its sensitivity. Tucked away in a hard-to-reach spot behind the stomach, it's in charge of secreting enzymes to help digest everything you eat. Even slightly puncturing the pancreas during surgery can cause it to begin digesting itself.

That may be in part why there is so little understanding of what causes pancreatitis, a fairly common and quite painful disorder of the gut.

"We try not to touch the pancreas," said Aida Habtezion, MD, assistant professor of gastroenterology and hepatology. "That's one of the reasons the field has not progressed much. We don't have much access to the pancreas. We especially don't want to touch it when it is inflamed with pancreatitis."

By working with animal models and cells retrieved from the few surgeries involving the human pancreas, Habtezion has spearheaded new research that provides insight for the first time into the molecular pathway that leads to , the debilitating, long-term form of the disease.

In a study published May 18 in Nature Communications, Habtezion and her colleagues found that blocking this pathway stops the progression of the uncontrolled growth of , or fibrosis, that's the hallmark of chronic pancreatitis.

"This is the first step to showing that you can alter the progression of this disease," said Habtezion, senior author of the study. The lead author is postdoctoral scholar Jing Xue, PhD.

Habtezion, a gastroenterologist with a background in immunology, splits her workdays between the lab and the hospital. Her interest in these patients has crossed over into her lab.

"Acute pancreatitis is one of the most common gastrointestinal admissions-related illnesses," she said. "Some people just have one or two episodes, and we never see them back." Others go on to develop chronic pancreatitis, which is a risk factor for cancer.

No known cure

Chronic pancreatitis is marked by constant, severe stomach pain. There is no known cure and little treatment beyond narcotics to help control the pain. The disease destroys the ability of the pancreas to absorb nutrients, leading to nutritional deficiencies and malnutrition, along with the crippling nausea and diarrhea caused by the abdominal pain. Key contributors to the disease include excessive alcohol consumption, gallstones and genetic factors.

"My lab has been interested in the inflammatory responses associated with pancreatitis and in understanding the molecular pathways that may be targeted to alter the progression of the disease," Habtezion said.

It's generally understood that chronic pancreatitis is marked by the uncontrolled growth of scar tissue in the pancreas, slowly destroying the organ's ability to function. Just how this happens is less clear.

In previous research, Habtezion's lab has shown that macrophages, a type of immune cell in the body, play a role in the acute form of pancreatitis. The goal of the new study was to determine the role of macrophages in the development of chronic pancreatitis from the acute form of the disease. Previous research has also shown that pancreatic stellate cells may play a role in fibrosis. These cells live in the pancreas and travel to injury sites when activated.

"Our most important finding was that there is cross-talk between macrophages and stellate cells," Habtezion said. "We identified this pathway." Next, they set out to determine if blocking this pathway would slow or stop fibrosis. This is where colleagues from Cedars-Sinai Medical Center—co-authors Stephen Pandol, MD, director of basic and translational research, and Ramachandran Murali, PhD, associate professor of biomedical sciences—helped out.

"Dr. Murali said, 'Oh, I have this agent that can block this receptor,'" Habtezion said. "He was developing the potential drug as treatment for another disease. We used this blocking peptide in both the animal models and the human cells."

When applied to the pathway, the pharmacological agent successfully slowed the fibrosis, she said.

"For the first time we can show that macrophages interact with pancreatic stellate cells via a particular immune pathway, and by targeting this pathway we show a decrease in chronic pancreatitis/fibrosis progression," she said. "This has great implication in a disease that has no active therapy with no known agents that can alter its natural devastating course."

Explore further: Smoking, alcohol, gene variant interact to increase risk of chronic pancreatitis

Related Stories

Smoking, alcohol, gene variant interact to increase risk of chronic pancreatitis

January 8, 2015
Genetic mutations may link smoking and alcohol consumption to destruction of the pancreas observed in chronic pancreatitis, according to a 12-year study led by researchers at the University of Pittsburgh School of Medicine. ...

Discovery of new signaling intermediates provides clues to novel therapies in pancreatitis

January 15, 2015
Signaling initiated by pancreatic digestive enzyme-producing (acinar) cells is essential to development of both pain and inflammation in pancreatitis, according to research published in the inaugural issue of Cellular and ...

Researchers decode origin of inflammation-driven pancreatic cancer

August 5, 2013
Researchers at Mayo Clinic in Florida have revealed the process by which chronic inflammation of the pancreas, pancreatitis, morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients ...

Insulin offers new hope for the treatment of acute pancreatitis

August 21, 2014
(Phys.org) —Scientists from The University of Manchester have discovered that insulin can protect the cells of the pancreas from acute pancreatitis – a disease for which there is currently no treatment.

Dendritic cells protect against acute pancreatitis

November 22, 2011
NYU Langone Medical Center researchers have discovered the novel protective role dendritic cells play in the pancreas. The new study, published in the November issue of journal Gastroenterology, shows dendritic cells can ...

Molecular master switch for pancreatic cancer identified, potential predictor of treatment outcome

February 12, 2013
A recently described master regulator protein may explain the development of aberrant cell growth in the pancreas spurred by inflammation

Recommended for you

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.